NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity RFA-DA-25-068 from the NIH Guide for Grants and Contracts. The scientific objective of this Notice of Funding Opportunity is to encourage research to delineate the role of inflammasomes in the neuropathology produced by acute or chronic drug exposure and HIV infection. Understanding the involvement of inflammasomes in virus and drug-induced immune activation may help identify molecular markers and CNS immune cells associated with HIV-1 infection or disease progression among substance abuse populations, as well as identify novel therapies to target inflammasome activation or suppression to treat neuroinflammation and immune dysregulation aroused in these processes.
Funding Opportunity RFA-DA-25-069 from the NIH Guide for Grants and Contracts. The scientific objective of this Notice of Funding Opportunity is to encourage research to delineate the role of inflammasomes in the neuropathology produced by acute or chronic drug exposure and HIV infection. Understanding the involvement of inflammasomes in virus and drug-induced immune activation may help identify molecular markers and CNS immune cells associated with HIV-1 infection or disease progression among substance abuse populations, as well as identify novel therapies to target inflammasome activation or suppression to treat neuroinflammation and immune dysregulation aroused in these processes.
Notice NOT-GM-25-002 from the NIH Guide for Grants and Contracts
Notice NOT-OD-24-180 from the NIH Guide for Grants and Contracts
Notice NOT-DA-24-053 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-25-053 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to encourage investigators to pursue translational activities and small clinical studies to advance the development of therapeutic, and diagnostic devices for disorders that affect the nervous or neuromuscular systems. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, obtaining an Investigational Device Exemption (IDE) for a Significant Risk (SR) study or Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study, as well as a subsequent small clinical study. The clinical study is expected to provide information about the device function or final design that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This NOFO is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in negotiating the final project plan before award and monitoring of research progress.
Notice NOT-DA-25-033 from the NIH Guide for Grants and Contracts
Notice NOT-CA-25-004 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-25-144 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, sustainability, scale-up, and spread of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies (hereafter referred to as evidence-based interventions).Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (de-implement) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. Applications that focus on re-implementation of evidence-based health services that may be disrupted amidst disasters (e.g., pandemics, climate change) remain relevant. All applications must be within the scope of the mission of one of the Institutes/Centers listed above.
Funding Opportunity PAR-25-131 from the NIH Guide for Grants and Contracts. NLM wishes to accelerate access to, and availability of, secure, complete datasets and computational models that can serve as the basis for transformative biomedical discoveries. Innovative at-scale computational approaches that increase the speed and scope of curation processes are needed for data mining and knowledge discovery from growing quantities of biomedical data being produced from ongoing data science advances.
Funding Opportunity PAR-24-265 from the NIH Guide for Grants and Contracts. The Shared Instrument Grant (SIG) Program encourages applications from groups of NIH-supported investigators to purchase or upgrade a single item of high-priced, specialized, commercially available instruments or integrated instrumentation system. The minimum award is $50,000. There is no maximum price limit for the instrument; however, the maximum award is $750,000. Instruments supported include, but are not limited to: light microscopes, biomedical imagers, mass spectrometers, nuclear magnetic resonance spectrometers, flow cytometers, DNA and protein sequencers, biosensors, and X-ray diffractometers.
Funding Opportunity PAR-24-264 from the NIH Guide for Grants and Contracts. The High-End Instrumentation (HEI) Grant Program encourages applications from groups of NIH-supported investigators to purchase or upgrade a single item of high-end, specialized, commercially available instruments or integrated systems. The minimum award is $750,001. There is no maximum price limit for the instrument; however, the maximum award is $2,000,000. Instruments supported include, but are not limited to, nuclear magnetic resonance spectrometers, X-ray diffractometers, mass spectrometers, high throughput robotic screening systems, DNA and protein sequencers, biosensors, electron and light microscopes, flow cytometers, and biomedical imagers.
Funding Opportunity PAR-24-326 from the NIH Guide for Grants and Contracts. The Basic Instrumentation Grant (BIG) Program encourages applications from groups of NIH-supported investigators to purchase a single piece of new, costly, specialized, commercially available instrument or an integrated instrumentation system. The BIG Program is limited to institutions that have not received S10 instrumentation funding of $500,001 or greater in any of the preceding 3 Federal fiscal years (FY). Use the following to determine applicable funding periods: for submission in CY 2026, consider S10 funding in FYs 2023-2025; for submission in CY 2027, consider S10 funding in FYs 2024-2026; for submission in CY 2028, consider S10 funding in FYs 2025-2027. The minimum award is $25,000. There is no maximum price limit for the instrument; however, the maximum award is $350,000. Instruments supported include, but are not limited to, basic cell sorters, confocal microscopes, ultramicrotomes, gel imagers, or computer systems.
Notice NOT-HS-25-007 from the NIH Guide for Grants and Contracts
Notice NOT-OD-25-008 from the NIH Guide for Grants and Contracts
Notice NOT-OD-25-006 from the NIH Guide for Grants and Contracts
Notice NOT-OD-25-007 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AG-25-027 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) from the National Institute on Aging (NIA) invites applications on T1 translational aging research (i.e., bench to bedside) which focus on advancing new therapeutics from preclinical stages to first-in-human (FIH) trials for aging-related conditions such as sarcopenia, heart failure with preserved ejection fraction (HFpEF), and deficits such as immunosenescence. The NOFO will specifically support two categories of milestone-driven projects: 1) traditional de novo drug development (i.e., new chemical/molecular entities) with three specific entry points to the translational pipeline (i.e., screening through preclinical validation, hit to lead through IND, or late-stage preclinical development through FIH studies), and 2) data-driven computational drug repurposing strategies with subsequent validation of predictions and generation of proof-of-concept data in pertinent animal models and/or in human in vitro studies.For the purposes of this NOFO, drug repurposing (also known as drug repositioning, reprofiling or re-tasking) refers to approaches for identifying alternative uses for FDA-approved drugs or investigational therapeutics which are beyond the scope of the original intended clinical indication. The types and scale of proposed translational research activities in the projects are anticipated to vary and will depend on whether the project focuses on traditional drug development pathways or involves drug repurposing. The UG3 phase of this NOFO will support T1 translational research planning activities and preliminary studies. Transition to the UH3 phase (based on achievement of UG3 milestones proposed by the investigators) will enable more comprehensive pharmacology and/or toxicology evaluations of the proposed therapeutics, including replication studies to confirm preliminary findings or experimental validation of predictive models.
Funding Opportunity PAR-25-024 from the NIH Guide for Grants and Contracts. The overarching purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and/or early evaluation of strong candidate biomarkers and biomarker signatures that can be used as tools to facilitate the clinical development of neurotherapeutics and their use in clinical practice. Specifically, the focus of this FOA is on the identification and initial biological, analytical and clinical evaluation of biomarkers and biomarker signatures for neurological and neuromuscular disorders. Although research supported by this FOA can include animal studies, it must also include preliminary human evaluation using carefully standardized human samples or datasets. The goal of this initiative is to deliver candidate biomarkers or biomarker signatures that are ready for definitive analytical and clinical validation studies.
Notice NOT-OD-25-009 from the NIH Guide for Grants and Contracts